{
    "info": {
        "nct_id": "NCT05652335",
        "official_title": "Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis",
        "inclusion_criteria": "For participants with relapsed or refractory multiple myeloma:\n\n* Have a documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria\n* Part 1: Have relapsed or refractory disease, have been treated with a proteasome inhibitor, immunomodulatory drug (IMiD) agent, and an anti-CD38-based therapy for the treatment of multiple myeloma (MM),and should have been treated with at least 3 prior lines of therapy, or are refractory to proteosome inhibitor, IMiD agent, and an anti-CD38-based therapy regardless of prior lines of therapy, Part 2: Have relapsed or refractory disease, have been treated with a PI, IMiD and an anti-CD38 based therapy\n* Must have an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1\n* Have measurable disease at screening as defined by at least 1 of the following: a) Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL); or b) Urine M-protein level >=200 milligrams (mg)/24 hours; or c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >=10 milligrams per deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio; d) For participants without measurable disease in the serum, urine, or involved FLC, presence of 1 or more focus of extramedullary disease (EMD) which meets the following criteria: extramedullary plasmacytoma not contiguous with a bone lesion, at least 1 lesion >=2 centimeter [cm] (at its greatest dimension) diameter on whole body Positron Emission Tomography and Computed Tomography (PET-CT) Scans (or whole body magnetic resonance imaging [MRI] approved by sponsor), and not previously radiated (Part 2C participants are not required to have measurable disease)\n\nFor participants with previously treated AL amyloidosis:\n\n* Initial histopathological diagnosis of amyloidosis\n* Participant who is not a candidate for available AL amyloidosis therapy with established clinical benefit and should have received at least 3 cycles of 1 prior line of therapy or a total of at least 2 cycles of 2 or more prior lines of therapy for AL amyloidosis\n* Measurable disease at screening defined by at least 1 of the following: serum involved free light chain (iFLC) >=50 mg/L or difference between involved and uninvolved free light chains (dFLC) >=50 mg/L, or serum m-protein >= 0.5 g/dL\n* One or more organs impacted by systemic AL amyloidosis\n* Left ventricular ejection fraction (LVEF) >=45%\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "For participants with relapsed or refractory multiple myeloma:\n\n* Central Nervous System (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required\n* Active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary light chain amyloidosis\n* Received a cumulative dose of corticosteroids equivalent to greater than (>) 140 mg of prednisone within the 14-day period before the start of study treatment administration\n* Prior antitumor therapy as follows, in the specified time frame prior to the first dose of study treatment: (proteasome inhibitor [PI] therapy or radiotherapy within 14 days, immunomodulatory drug (IMiD) agent therapy within 7 days, gene-modified adoptive cell therapy within 90 days [not applicable for Part 2C participants], or CD3-redirecting therapy within 21 days[not applicable for Part 2B or 2C participants])\n* Prior allogeneic transplant within 6 months before the start of study treatment administration or autologous transplant within 12 weeks before the start of study treatment administration\n* Live, attenuated vaccine within 4 weeks before the first dose of study treatment\n* Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (<=) 1 (except alopecia, tissue post-RT fibrosis [any grade] or peripheral neuropathy to Grade <=3)\n* The following medical conditions: pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation, human immunodeficiency (HIV) infection, active hepatitis B or C infection, stroke or seizure within 6 months prior to first dose of study treatment, autoimmune disease, serious active viral or bacterial infection, uncontrolled systemic fungal infection, cardiac conditions (myocardial infarction <=6 months prior to enrollment, New York Heart Association stage III or IV congestive heart failure, et cetera)\n* Part 2C: have progressive disease or refractory disease per IMWG after CAR-T administration\n\nFor participants with previously treated AL amyloidosis:\n\n* CNS involvement or clinical signs of meningeal involvement of AL amyloidosis. If either is suspected, whole brain MRI and lumbar cytology are required\n* Any form of non-AL amyloidosis, including but not limited to transthyretin (ATTR) amyloidosis\n* Active plasma cell leukemia, Waldenstrom's macroglobulinemia, or POEMS syndrome\n* Pulmonary compromise requiring supplemental oxygen use\n* Any serious medical conditions such as: active viral, bacterial, fungal infection; active autoimmune disease; HIV infection, active hepatitis B or C infection, stroke or seizure within 6 months prior to first dose of study treatment, significant cardiovascular conditions\n* Previous or current diagnosis of symptomatic multiple myeloma\n* Macroglossia that impairs swallowing difficulty\n* Received a cumulative dose of corticosteroids equivalent to > 140 mg of prednisone within the 14-day period before the start of study treatment administration\n* Prior antitumor therapy within 21 days prior to the first dose of study treatment (PI therapy or radiotherapy within 14 days, IMiD agent therapy within 7 days, gene-modified adoptive cell therapy within 90 days, or CD3-redirecting therapy within 21 days)\n* Prior allogeneic transplant within 6 months before the start of study treatment administration or autologous transplant within 12 weeks before the start of study treatment administration\n* Live, attenuated vaccine within 4 weeks before the first dose of study treatment\n* Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to <=1 (except alopecia, tissue post-RT fibrosis [any grade] or peripheral neuropathy to Grade <=3)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Must have an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Must have an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1",
                    "criterion": "Eastern Cooperative Oncology Group (ECOG) status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have a documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria",
            "criterions": [
                {
                    "exact_snippets": "documented initial diagnosis of multiple myeloma",
                    "criterion": "multiple myeloma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "initial diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "according to International Myeloma Working Group (IMWG) diagnostic criteria",
                    "criterion": "IMWG diagnostic criteria for multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "diagnostic standard",
                            "expected_value": "International Myeloma Working Group (IMWG) criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Initial histopathological diagnosis of amyloidosis",
            "criterions": [
                {
                    "exact_snippets": "Initial histopathological diagnosis of amyloidosis",
                    "criterion": "histopathological diagnosis of amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "initial"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "For participants with previously treated AL amyloidosis:",
            "criterions": [
                {
                    "exact_snippets": "previously treated AL amyloidosis",
                    "criterion": "AL amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* One or more organs impacted by systemic AL amyloidosis",
            "criterions": [
                {
                    "exact_snippets": "One or more organs impacted by systemic AL amyloidosis",
                    "criterion": "organs impacted by systemic AL amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "organs"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) >=45%",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) >=45%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Part 1: Have relapsed or refractory disease, have been treated with a proteasome inhibitor, immunomodulatory drug (IMiD) agent, and an anti-CD38-based therapy for the treatment of multiple myeloma (MM),and should have been treated with at least 3 prior lines of therapy, or are refractory to proteosome inhibitor, IMiD agent, and an anti-CD38-based therapy regardless of prior lines of therapy, Part 2: Have relapsed or refractory disease, have been treated with a PI, IMiD and an anti-CD38 based therapy",
            "criterions": [
                {
                    "exact_snippets": "relapsed or refractory disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have been treated with a proteasome inhibitor, immunomodulatory drug (IMiD) agent, and an anti-CD38-based therapy",
                    "criterion": "prior therapies received",
                    "requirements": [
                        {
                            "requirement_type": "therapies_received",
                            "expected_value": [
                                "proteasome inhibitor",
                                "immunomodulatory drug (IMiD) agent",
                                "anti-CD38-based therapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "treatment of multiple myeloma (MM)",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "multiple myeloma"
                        }
                    ]
                },
                {
                    "exact_snippets": "should have been treated with at least 3 prior lines of therapy",
                    "criterion": "number of prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "number_of_prior_lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory to proteosome inhibitor, IMiD agent, and an anti-CD38-based therapy regardless of prior lines of therapy",
                    "criterion": "refractoriness to therapies",
                    "requirements": [
                        {
                            "requirement_type": "refractory_to",
                            "expected_value": [
                                "proteasome inhibitor",
                                "IMiD agent",
                                "anti-CD38-based therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "For participants with relapsed or refractory multiple myeloma:",
            "criterions": [
                {
                    "exact_snippets": "relapsed or refractory multiple myeloma",
                    "criterion": "multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease at screening defined by at least 1 of the following: serum involved free light chain (iFLC) >=50 mg/L or difference between involved and uninvolved free light chains (dFLC) >=50 mg/L, or serum m-protein >= 0.5 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease at screening defined by at least 1 of the following: serum involved free light chain (iFLC) >=50 mg/L",
                    "criterion": "serum involved free light chain (iFLC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mg/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "difference between involved and uninvolved free light chains (dFLC) >=50 mg/L",
                    "criterion": "difference between involved and uninvolved free light chains (dFLC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mg/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serum m-protein >= 0.5 g/dL",
                    "criterion": "serum m-protein",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant who is not a candidate for available AL amyloidosis therapy with established clinical benefit and should have received at least 3 cycles of 1 prior line of therapy or a total of at least 2 cycles of 2 or more prior lines of therapy for AL amyloidosis",
            "criterions": [
                {
                    "exact_snippets": "Participant who is not a candidate for available AL amyloidosis therapy with established clinical benefit",
                    "criterion": "candidate status for available AL amyloidosis therapy with established clinical benefit",
                    "requirements": [
                        {
                            "requirement_type": "candidate status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "should have received at least 3 cycles of 1 prior line of therapy",
                    "criterion": "prior AL amyloidosis therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines of therapy",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "number of cycles received",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "cycles"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "or a total of at least 2 cycles of 2 or more prior lines of therapy",
                    "criterion": "prior AL amyloidosis therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines of therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "number of cycles received",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "cycles"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have measurable disease at screening as defined by at least 1 of the following: a) Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL); or b) Urine M-protein level >=200 milligrams (mg)/24 hours; or c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >=10 milligrams per deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio; d) For participants without measurable disease in the serum, urine, or involved FLC, presence of 1 or more focus of extramedullary disease (EMD) which meets the following criteria: extramedullary plasmacytoma not contiguous with a bone lesion, at least 1 lesion >=2 centimeter [cm] (at its greatest dimension) diameter on whole body Positron Emission Tomography and Computed Tomography (PET-CT) Scans (or whole body magnetic resonance imaging [MRI] approved by sponsor), and not previously radiated (Part 2C participants are not required to have measurable disease)",
            "criterions": [
                {
                    "exact_snippets": "measurable disease at screening",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL)",
                    "criterion": "serum M-protein level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "g/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Urine M-protein level >=200 milligrams (mg)/24 hours",
                    "criterion": "urine M-protein level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 200,
                                "unit": "mg/24 hours"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >=10 milligrams per deciliter (mg/dL)",
                    "criterion": "serum immunoglobulin free light chain (FLC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "abnormal serum Ig kappa lambda FLC ratio",
                    "criterion": "serum Ig kappa lambda FLC ratio",
                    "requirements": [
                        {
                            "requirement_type": "abnormality",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of 1 or more focus of extramedullary disease (EMD)",
                    "criterion": "extramedullary disease (EMD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "extramedullary plasmacytoma not contiguous with a bone lesion",
                    "criterion": "extramedullary plasmacytoma not contiguous with a bone lesion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 1 lesion >=2 centimeter [cm] (at its greatest dimension) diameter",
                    "criterion": "extramedullary lesion size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "on whole body Positron Emission Tomography and Computed Tomography (PET-CT) Scans (or whole body magnetic resonance imaging [MRI] approved by sponsor)",
                    "criterion": "imaging modality for lesion assessment",
                    "requirements": [
                        {
                            "requirement_type": "modality",
                            "expected_value": [
                                "whole body PET-CT",
                                "whole body MRI (approved by sponsor)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "not previously radiated",
                    "criterion": "prior radiation to lesion",
                    "requirements": [
                        {
                            "requirement_type": "prior radiation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Received a cumulative dose of corticosteroids equivalent to > 140 mg of prednisone within the 14-day period before the start of study treatment administration",
            "criterions": [
                {
                    "exact_snippets": "Received a cumulative dose of corticosteroids equivalent to > 140 mg of prednisone within the 14-day period before the start of study treatment administration",
                    "criterion": "cumulative corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 140,
                                "unit": "mg prednisone"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within the 14-day period before the start of study treatment administration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CNS involvement or clinical signs of meningeal involvement of AL amyloidosis. If either is suspected, whole brain MRI and lumbar cytology are required",
            "criterions": [
                {
                    "exact_snippets": "CNS involvement or clinical signs of meningeal involvement of AL amyloidosis",
                    "criterion": "CNS involvement of AL amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical signs of meningeal involvement of AL amyloidosis",
                    "criterion": "meningeal involvement of AL amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "clinical signs",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "For participants with previously treated AL amyloidosis:",
            "criterions": [
                {
                    "exact_snippets": "previously treated AL amyloidosis",
                    "criterion": "AL amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previous or current diagnosis of symptomatic multiple myeloma",
            "criterions": [
                {
                    "exact_snippets": "Previous or current diagnosis of symptomatic multiple myeloma",
                    "criterion": "symptomatic multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_status",
                            "expected_value": [
                                "previous",
                                "current"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received a cumulative dose of corticosteroids equivalent to greater than (>) 140 mg of prednisone within the 14-day period before the start of study treatment administration",
            "criterions": [
                {
                    "exact_snippets": "Received a cumulative dose of corticosteroids equivalent to greater than (>) 140 mg of prednisone within the 14-day period before the start of study treatment administration",
                    "criterion": "cumulative corticosteroid dose (prednisone equivalent)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 140,
                                "unit": "mg"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within the 14-day period before the start of study treatment administration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The following medical conditions: pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation, human immunodeficiency (HIV) infection, active hepatitis B or C infection, stroke or seizure within 6 months prior to first dose of study treatment, autoimmune disease, serious active viral or bacterial infection, uncontrolled systemic fungal infection, cardiac conditions (myocardial infarction <=6 months prior to enrollment, New York Heart Association stage III or IV congestive heart failure, et cetera)",
            "criterions": [
                {
                    "exact_snippets": "pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation",
                    "criterion": "pulmonary compromise",
                    "requirements": [
                        {
                            "requirement_type": "supplemental oxygen use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "human immunodeficiency (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B or C infection",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B or C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "stroke or seizure within 6 months prior to first dose of study treatment",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "stroke or seizure within 6 months prior to first dose of study treatment",
                    "criterion": "seizure",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "serious active viral or bacterial infection",
                    "criterion": "serious active viral infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious active viral or bacterial infection",
                    "criterion": "serious active bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled systemic fungal infection",
                    "criterion": "systemic fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction <=6 months prior to enrollment",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association stage III or IV congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA stage",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any form of non-AL amyloidosis, including but not limited to transthyretin (ATTR) amyloidosis",
            "criterions": [
                {
                    "exact_snippets": "Any form of non-AL amyloidosis, including but not limited to transthyretin (ATTR) amyloidosis",
                    "criterion": "non-AL amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active plasma cell leukemia, Waldenstrom's macroglobulinemia, or POEMS syndrome",
            "criterions": [
                {
                    "exact_snippets": "Active plasma cell leukemia",
                    "criterion": "plasma cell leukemia",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "Waldenstrom's macroglobulinemia",
                    "criterion": "Waldenstrom's macroglobulinemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "POEMS syndrome",
                    "criterion": "POEMS syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to <=1 (except alopecia, tissue post-RT fibrosis [any grade] or peripheral neuropathy to Grade <=3)",
            "criterions": [
                {
                    "exact_snippets": "Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to <=1",
                    "criterion": "non-hematologic toxicity from prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "any grade"
                        }
                    ]
                },
                {
                    "exact_snippets": "tissue post-RT fibrosis [any grade]",
                    "criterion": "tissue post-radiation fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "any grade"
                        }
                    ]
                },
                {
                    "exact_snippets": "peripheral neuropathy to Grade <=3",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any serious medical conditions such as: active viral, bacterial, fungal infection; active autoimmune disease; HIV infection, active hepatitis B or C infection, stroke or seizure within 6 months prior to first dose of study treatment, significant cardiovascular conditions",
            "criterions": [
                {
                    "exact_snippets": "active viral, bacterial, fungal infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "viral",
                                "bacterial",
                                "fungal"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HIV infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B or C infection",
                    "criterion": "hepatitis B or C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "stroke or seizure within 6 months prior to first dose of study treatment",
                    "criterion": "stroke or seizure",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "significant cardiovascular conditions",
                    "criterion": "cardiovascular conditions",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary light chain amyloidosis",
            "criterions": [
                {
                    "exact_snippets": "Active plasma cell leukemia",
                    "criterion": "plasma cell leukemia",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "Waldenstrom's macroglobulinemia",
                    "criterion": "Waldenstrom's macroglobulinemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes)",
                    "criterion": "POEMS syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "primary light chain amyloidosis",
                    "criterion": "primary light chain amyloidosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "For participants with relapsed or refractory multiple myeloma:",
            "criterions": [
                {
                    "exact_snippets": "relapsed or refractory multiple myeloma",
                    "criterion": "multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "disease_status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior antitumor therapy within 21 days prior to the first dose of study treatment (PI therapy or radiotherapy within 14 days, IMiD agent therapy within 7 days, gene-modified adoptive cell therapy within 90 days, or CD3-redirecting therapy within 21 days)",
            "criterions": [
                {
                    "exact_snippets": "Prior antitumor therapy within 21 days prior to the first dose of study treatment",
                    "criterion": "prior antitumor therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "PI therapy or radiotherapy within 14 days",
                    "criterion": "PI therapy or radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "IMiD agent therapy within 7 days",
                    "criterion": "IMiD agent therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "gene-modified adoptive cell therapy within 90 days",
                    "criterion": "gene-modified adoptive cell therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "CD3-redirecting therapy within 21 days",
                    "criterion": "CD3-redirecting therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic transplant within 6 months before the start of study treatment administration or autologous transplant within 12 weeks before the start of study treatment administration",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic transplant within 6 months before the start of study treatment administration",
                    "criterion": "prior allogeneic transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "autologous transplant within 12 weeks before the start of study treatment administration",
                    "criterion": "prior autologous transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Part 2C: have progressive disease or refractory disease per IMWG after CAR-T administration",
            "criterions": [
                {
                    "exact_snippets": "have progressive disease ... after CAR-T administration",
                    "criterion": "progressive disease after CAR-T administration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have ... refractory disease per IMWG after CAR-T administration",
                    "criterion": "refractory disease after CAR-T administration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition",
                            "expected_value": "per IMWG"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Macroglossia that impairs swallowing difficulty",
            "criterions": [
                {
                    "exact_snippets": "Macroglossia that impairs swallowing difficulty",
                    "criterion": "macroglossia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "impairs swallowing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Central Nervous System (CNS) involvement or clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required",
            "criterions": [
                {
                    "exact_snippets": "Central Nervous System (CNS) involvement ... of multiple myeloma",
                    "criterion": "CNS involvement of multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinical signs of meningeal involvement of multiple myeloma",
                    "criterion": "meningeal involvement of multiple myeloma",
                    "requirements": [
                        {
                            "requirement_type": "clinical signs",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Live, attenuated vaccine within 4 weeks before the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Live, attenuated vaccine within 4 weeks before the first dose of study treatment",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration before first dose of study treatment",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior antitumor therapy as follows, in the specified time frame prior to the first dose of study treatment: (proteasome inhibitor [PI] therapy or radiotherapy within 14 days, immunomodulatory drug (IMiD) agent therapy within 7 days, gene-modified adoptive cell therapy within 90 days [not applicable for Part 2C participants], or CD3-redirecting therapy within 21 days[not applicable for Part 2B or 2C participants])",
            "criterions": [
                {
                    "exact_snippets": "proteasome inhibitor [PI] therapy or radiotherapy within 14 days",
                    "criterion": "prior proteasome inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "proteasome inhibitor [PI] therapy or radiotherapy within 14 days",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "immunomodulatory drug (IMiD) agent therapy within 7 days",
                    "criterion": "prior immunomodulatory drug (IMiD) agent therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "gene-modified adoptive cell therapy within 90 days [not applicable for Part 2C participants]",
                    "criterion": "prior gene-modified adoptive cell therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "not applicable for Part 2C participants"
                        }
                    ]
                },
                {
                    "exact_snippets": "CD3-redirecting therapy within 21 days[not applicable for Part 2B or 2C participants]",
                    "criterion": "prior CD3-redirecting therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "not applicable for Part 2B or 2C participants"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Live, attenuated vaccine within 4 weeks before the first dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Live, attenuated vaccine within 4 weeks before the first dose of study treatment",
                    "criterion": "live, attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration before first dose of study treatment",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic transplant within 6 months before the start of study treatment administration or autologous transplant within 12 weeks before the start of study treatment administration",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic transplant within 6 months before the start of study treatment administration",
                    "criterion": "prior allogeneic transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "autologous transplant within 12 weeks before the start of study treatment administration",
                    "criterion": "prior autologous transplant",
                    "requirements": [
                        {
                            "requirement_type": "time since transplant",
                            "expected_value": {
                                "operator": "<",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (<=) 1 (except alopecia, tissue post-RT fibrosis [any grade] or peripheral neuropathy to Grade <=3)",
            "criterions": [
                {
                    "exact_snippets": "Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (<=) 1",
                    "criterion": "non-hematologic toxicity from prior anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "any grade"
                        }
                    ]
                },
                {
                    "exact_snippets": "tissue post-RT fibrosis [any grade]",
                    "criterion": "tissue post-RT fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "any grade"
                        }
                    ]
                },
                {
                    "exact_snippets": "peripheral neuropathy to Grade <=3",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pulmonary compromise requiring supplemental oxygen use",
            "criterions": [
                {
                    "exact_snippets": "Pulmonary compromise requiring supplemental oxygen use",
                    "criterion": "pulmonary compromise",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "requiring supplemental oxygen use"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}